Skip to main content
main-content

Type 2 diabetes and cardiovascular disease

medwireNews top story

Type 1 diabetes identified in earliest weeks of life

Kidneys

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

medwireNews top story

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Heart and white pills

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

EASD 2020

EMPEROR-Reduced: Time for a change in the HF guidelines?

Miles Fisher

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

EASD 2020

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

Hiddo Heerspink

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

EASD 2020

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

Milton Packer

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

EASD 2020 News

LIBERATES trial results: Hypoglycemia reduction with post-ACS flash monitoring in type 2 diabetes

Woman with flash glucose monitor (symbolic image with model)

The results of the phase 2 LIBERATES trial suggest that flash glucose monitoring could reduce the time people with type 2 diabetes spend in hypoglycemia in the period following an acute coronary syndrome.

medwireNews top story

SGLT2 inhibition ‘could overcome diuretic resistance’

Man handing container with urine sample to a doctor

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

medwireNews top story

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

Flatline alert_heart monitor

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

medwireNews top story

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

Pills and water (symbolic image with model)

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

medwireNews top story

Nonvascular comorbidities highlighted in type 2 diabetes

Doctor patient consultation

A large study of data from people with type 2 diabetes in general practice reveals that non-cardiovascular comorbidities such as osteoarthritis and depression are common, and significantly more so than in people without diabetes.

medwireNews

10-26-2020 | Early onset | News

Researchers propose early-onset type 2 diabetes phenotype

Younger age at onset of type 2 diabetes is associated with a significantly increased risk for cardiovascular death, as well as an increased likelihood of having offspring who will also develop diabetes, Framingham Heart Study data show.

10-23-2020 | Nephropathy | News

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

10-12-2020 | Ertugliflozin | Highlight | News

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-28-2018 | Diabetic cardiomyopathy | Article

Cardiovascular risk reduction over time in patients with diabetes or pre-diabetes undergoing bariatric surgery: data from a single-center retrospective observational study

Rubio-Almanza M, Cámara-Gómez R, Hervás-Marín D et al. BMC Endocr Disord 2018; 18: 90. doi: 10.1186/s12902-018-0317-4

11-21-2018 | Cardiovascular disorders | Review | Article

Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

Schernthaner G et al. Cardiovasc Diabetol 2018; 17: 145. doi: 10.1186/s12933-018-0788-7

11-10-2018 | Retinopathy | Article

Diabetic retinopathy grade as a predictive marker of severity of cardiovascular disease and mortality: DIVERSE Study Group

Shah K et al. Int J Diabetes Dev Ctries 2018. doi: 10.1007/s13410-018-0699-x

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits